FDA accepts NDA for oral Remodulin (United Therapeutics) for PAH - 22-Feb-2012

The FDA has accepted for review the new drug application (NDA) for oral Remodulin (treprostinil diethanolamine sustained release), from United Therapeutics, for the treatment of Pulmonary Arterial Hypertension. The NDA will be subjected to a standard 10-month review period, with a targeted user fee deadline of October 27, 2012.

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013